Active Ingredient History
Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, indicated for the treatment of adult patients with Cushing’s disease for whom pituitary surgery is not an option or has not been curative. SIGNIFOR is an injectable cyclohexapeptide somatostatin analogue. Pasireotide exerts its pharmacological activity via binding to somatostatin receptors (ssts). Pasireotide binds and activates the hsst receptors resulting in inhibition of ACTH secretion, which leads to decreased cortisol secretion. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Pituitary ACTH Hypersecretion (approved 2012)
Acromegaly (Phase 4)
ACTH Syndrome, Ectopic (Phase 2)
Adenoma (Phase 2)
Adenoma, Islet Cell (Phase 2)
Alcoholism (Phase 1)
Angiodysplasia (Phase 2)
Bariatric Surgery (Phase 2)
Breast Carcinoma In Situ (Phase 1)
Breast Neoplasms (Phase 2)
Carcinoid Tumor (Phase 3)
Carcinoma, Hepatocellular (Phase 2)
Carcinoma, Intraductal, Noninfiltrating (Phase 2)
Congenital Hyperinsulinism (Phase 2)
Cushing Syndrome (Phase 2)
Drugs, Investigational (Phase 2)
Dumping Syndrome (Phase 4)
Enterostomy (Phase 2)
General Surgery (Phase 4)
Gigantism (Phase 2)
Headache (Phase 2)
Healthy Volunteers (Phase 1)
Hematologic Neoplasms (Phase 2)
Hyperglycemia (Phase 2)
Hyperinsulinism (Phase 2)
Hyperplasia (Phase 1)
Hypoglycemia (Phase 4)
Insulinoma (Phase 2)
Intestinal Neoplasms (Phase 1)
Kidney Failure, Chronic (Phase 1)
Liver Cirrhosis (Phase 1)
Liver Diseases (Phase 3)
Lung Neoplasms (Phase 2)
Melanoma (Phase 4)
Meningioma (Phase 2)
Multiple Myeloma (Phase 2)
Nelson Syndrome (Phase 2)
Neoplasms (Phase 4)
Neuroendocrine Tumors (Phase 4)
Obesity (Phase 4)
Pancreatic Fistula (Phase 4)
Pancreatic Neoplasms (Phase 4)
Peritoneal Neoplasms (Phase 2)
Pituitary ACTH Hypersecretion (Phase 4)
Pituitary Neoplasms (Phase 4)
Polycystic Kidney, Autosomal Dominant (Phase 2)
Postoperative Complications (Phase 2)
Prolactinoma (Phase 2/Phase 3)
Prostatic Neoplasms (Phase 4)
Small Cell Lung Carcinoma (Phase 2)
Thymoma (Phase 2)
Thyroid Neoplasms (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue